• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Vapotherm Inc.

    9/24/24 7:04:57 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care
    Get the next $VAPO alert in real time by email
    SC 13D/A 1 d873616dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Vapotherm, Inc.

    (Name of Issuer)

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

    922107305

    (CUSIP Number)

    Alexander Rakitin

    Perceptive Advisors LLC

    51 Astor Place, 10th Floor

    New York, NY 10003

    (646) 205-5340

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    September 20, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 922107305

     

     1.    

     Names of Reporting Persons.

     

     Perceptive Advisors LLC

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     NA

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     0

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     0

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     0

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     0

    14.  

     Type of Reporting Person (See Instructions)

     

     OO


    CUSIP No. 922107305

     

     1.    

     Names of Reporting Persons.

     

     Joseph Edelman

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     NA

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States of America

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     0

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     0

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     0

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     0

    14.  

     Type of Reporting Person (See Instructions)

     

     IN


    CUSIP No. 922107305

     

     1.    

     Names of Reporting Persons.

     

     Veronica Intermediate Holdings, LLC

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     NA

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     1,000

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     1,000

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,000

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     100%

    14.  

     Type of Reporting Person (See Instructions)

     

     OO


    CUSIP No. 922107305

     

     1.    

     Names of Reporting Persons.

     

     Veronica Holdings, LLC

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     NA

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     United States of America

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     1,000

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     1,000

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,000

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     100%

    14.  

     Type of Reporting Person (See Instructions)

     

     OO


     

    Item 2.

    Identity and Background

    Item 2 of the Schedule 13D is amended and supplemented as follows:

    Veronica Intermediate Holdings, LLC (“Veronica Intermediate”) is a wholly owned subsidiary of Veronica Holdings, LLC (“Veronica”). In connection with the Merger (as defined below in Item 4 of this Amendment No. 1), the individuals set forth in Schedule A hereto, which is incorporated by reference to this Item 2, were appointed as the officers and directors of Veronica.

    To the knowledge of the Reporting Persons, none of the individuals set forth in Schedule A hereto have been during the last five years, a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    Item 3.

    Source and Amount of Funds or Other Consideration

    Item 3 of the Schedule 13D is amended and supplemented as follows:

    The information set forth below in Item 5 of this Amendment No. 1 to Schedule 13D is incorporated by reference into this Item 3.

     

    Item 4.

    Purpose of Transaction

    Item 4 of the Schedule 13D is amended and supplemented as follows. Each capitalized term in this Item 4 that is not otherwise defined in this Schedule 13D shall have the meaning set forth in the Merger Agreement (as defined herein):

    The Merger and Merger Agreement

    As previously disclosed, on June 17, 2024, Vapotherm, Inc. (the “Issuer”) entered into an Agreement and Plan of Merger (the “Merger Agreement”), dated as of June 17, 2024, among Veronica, Veronica Intermediate, Veronica Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Veronica Intermediate (“Merger Sub”), and the Issuer.

    On September 19, 2024, a special meeting of stockholders of the Issuer was held (the “Special Meeting”). At the Special Meeting, the Issuer’s stockholders voted to approve the proposal to adopt the Merger Agreement by the affirmative vote of the holders of at least a majority of the shares of the Issuer’s Common Stock outstanding as of the close of business on the record date of the Special Meeting.

    On September 20, 2024, pursuant to the Merger Agreement and in accordance with the applicable provisions of the General Corporation Law of the State of Delaware, the Issuer filed a certificate of merger with the Secretary of State of the State of Delaware, pursuant to which the Merger became effective. As a result of the Merger, the separate corporate existence of Merger Sub ceased, and the Issuer continued as the surviving corporation of the Merger and as a wholly owned subsidiary of Veronica Intermediate.

    Pursuant to the Merger Agreement, at the Effective Time, and by virtue of the Merger, each Share, other than the Excluded Shares, was automatically cancelled and converted into the right to receive the Per Share Merger Consideration, without interest thereon and subject to applicable withholding.

    As a result of the Merger, the Shares no longer trade on the OTCQX tier of the OTC Markets or any other over-the-counter market. In addition, in connection with the consummation of the Merger, the Issuer intends to file with the SEC a certification and notice of termination of registration on Form 15 with respect to the Issuer’s Common Stock, requesting that the Issuer’s Common Stock be deregistered under Section 12(g) of the Act and that the reporting obligations of the Issuer with respect to the Issuer’s Common Stock under Sections 13(a) and 15(d) of the Act be suspended.


    As a result of the Merger, the Rollover, and the Subscription Agreement, the equity investors in Veronica consist primarily of each of the SLR Rollover Holders (as defined in the Issuer’s Current Report on Form 8-K filed with the SEC on September 20, 2024), funds managed by affiliates of Perceptive, the Stockholder Rollover Holders and the Subscribers.

    The above description of the Merger Agreement is qualified in its entirety by reference to the terms of the agreement, which is filed as Exhibit 2 to the initial Schedule 13D and incorporated by reference into this Item 4.

    The Rollover Agreements

    On the Closing Date and immediately prior to the Effective Time, certain stockholders of the Issuer (the “Stockholder Rollover Holders”), including stockholders who executed Rollover Agreements after the execution of the Merger Agreement, contributed, transferred and assigned to Veronica all or a portion of the Shares held directly by such Stockholder Rollover Holder (the “Rollover Shares”), in exchange for Veronica Common Units at a price per Veronica Common Unit equal to $2.18 pursuant to the terms of the applicable Rollover Agreements. In connection with the Closing, the grant to Veronica and its designees of the Rollover Stockholders’ proxy and attorney-in-fact expired.

    The above description of the Rollover Agreements is qualified in its entirety by reference to the terms of the agreements, the forms of which are filed as Exhibit 3 and Exhibit 4 to the initial Schedule 13D and incorporated by reference into this Item 4.

    The Subscription Agreements

    On the Closing Date and immediately following the Effective Time, certain members of the Issuer’s management and certain other employees of the Issuer (collectively, the “Subscribers”) purchased from Veronica a number of Veronica Common Units, in each case as determined pursuant to the applicable Subscription Agreement, at a subscription price of $2.18 per Veronica Common Unit, which number of Veronica Common Units was determined by calculating (a) all or a portion of such Subscriber’s consideration payable (net of withholding taxes, except as otherwise agreed by the Subscriber) in respect of such Subscriber’s Company Equity Awards, divided by (b) a price per Veronica Common Unit equal to $2.18. In addition, certain additional holders of the Issuer’s Shares acquired Veronica Common Units on the same economic terms and at a price per Unit equal to the Per Share Merger Consideration.

    The above description of the Subscription Agreements is qualified in its entirety by reference to the terms of the agreement, the form of which is filed as Exhibit 5 to the initial Schedule 13D and incorporated by reference into this Item 4.

    The Voting Agreements

    In connection with the Closing, the grants by the Voting Parties to Veronica Intermediate and its designees of such Voting Party’s proxy and attorney-in-fact to vote all of the Covered Shares or execute and deliver a consent or approval in respect of the Covered Shares pursuant to the terms of the applicable Voting Agreements expired.

    The above description of the Voting Agreements is qualified in its entirety by reference to the terms of the agreements, the form of which is filed as Exhibit 6 to the initial Schedule 13D and incorporated by reference into this Item 4.

     

    Item 5.

    Interest in Securities of the Issuer

    Item 5 of the Schedule 13D is amended and supplemented as follows:

     

      (a)

    The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The share numbers and percentages reported on the cover pages give effect to the Merger described in Item 4 of this Amendment No. 1.


      (b)

    As a result of the Merger, the Issuer is now a wholly-owned subsidiary of Veronica Intermediate, which is a wholly owned subsidiary of Veronica. Veronica is owned primarily by the SLR Rollover Holders, funds managed by affiliates of Perceptive, the Stockholder Rollover Holders and the Subscribers.

     

      (c)

    Other than as described in this Schedule 13D, none of the Reporting Persons has effected any transactions in the Common Stock during the past sixty days.

     

      (d)

    Veronica Intermediate is a wholly owned subsidiary of Veronica. The equity investors in Veronica consist primarily of the SLR Rollover Holders, funds managed by affiliates of Perceptive, the Stockholder Rollover Holders and the Subscribers.

     

      (e)

    In connection with the Merger, on the Closing Date, Veronica acquired all of the outstanding Shares of the Issuer and the Issuer became a wholly owned subsidiary of Veronica. Accordingly, the Reporting Persons will not file any further amendment to this Schedule 13D.


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: September 24, 2024

     

    PERCEPTIVE ADVISORS LLC
    By:  

    /s/ Joseph Edelman

      Name: Joseph Edelman
    Title:   Managing Member

    /s/ Joseph Edelman

    JOSEPH EDELMAN
    VERONICA INTERMEDIATE HOLDINGS, LLC
    By:  

    /s/ Konstantin Poukalov

      Name: Konstantin Poukalov
    Title:   President
    VERONICA HOLDINGS, LLC
    By:  

    /s/ Konstantin Poukalov

      Name: Konstantin Poukalov
    Title:   Director


    Schedule A

    The officers and directors of Veronica Holdings, LLC, as well as their title, occupation, business address, and citizenship, are set forth in the following table:

     

    Name

      

    Title

      

    Occupation

      

    Business

    Address

      

    Citizenship

    Konstantin Poukalov    Director    Managing Director & Perceptive Discovery Co-Head, Perceptive Advisors LLC   

    c/o Perceptive Advisors LLC

    51 Astor Place, 10th Floor

    New York, NY 10003

       United States
    Anthony Storino    Director    Partner, Head of Life Science Finance, SLR Capital Partners   

    500 Park Avenue, 3rd Floor,

    New York, NY 10022

       United States
    Edan Yacobovsky    Director    Partner, SLR Capital Partners   

    500 Park Avenue, 3rd Floor,

    New York, NY 10022

       United States
    Carlos Vazquez    Director    Vice President, Perceptive Advisors LLC   

    c/o Perceptive Advisors LLC

    51 Astor Place, 10th Floor

    New York, NY 10003

       United Kingdom; Spain
    Joe Army    Director    Chief Executive Officer, Vapotherm, Inc.   

    c/o Perceptive Advisors LLC

    51 Astor Place, 10th Floor

    New York, NY 10003

       United States
    Get the next $VAPO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VAPO

    DatePrice TargetRatingAnalyst
    5/6/2022$12.00 → $5.00Buy → Hold
    Canaccord Genuity
    4/7/2022$23.00 → $8.00Overweight → Underweight
    Piper Sandler
    More analyst ratings

    $VAPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Arnerich Anthony L. bought $117,337 worth of shares (37,750 units at $3.11), increasing direct ownership by 263% to 24,509 units (SEC Form 4) (Amendment)

      4/A - VAPOTHERM INC (0001253176) (Issuer)

      10/4/23 4:11:34 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Arnerich Anthony L. returned $344,305 worth of shares to the company (232,993 units at $1.48), closing all direct ownership in the company (SEC Form 4)

      4 - VAPOTHERM INC (0001253176) (Issuer)

      9/24/24 5:01:08 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • President and CEO Army Joseph returned $43,419 worth of shares to the company (452,698 units at $0.10), closing all direct ownership in the company (SEC Form 4)

      4 - VAPOTHERM INC (0001253176) (Issuer)

      9/24/24 4:43:19 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SVP & Chief Financial Officer Landry John returned $51,982 worth of shares to the company (71,661 units at $0.73), closing all direct ownership in the company (SEC Form 4)

      4 - VAPOTHERM INC (0001253176) (Issuer)

      9/24/24 4:14:26 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $VAPO
    Leadership Updates

    Live Leadership Updates

    See more
    • Vapotherm Announces Closing of Merger

      EXETER, N.H., Sept. 20, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has closed its merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC. On June 17, 2024, the Company announced that it had signed a definitive agreement and plan of merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund. Concurrently with the entry into the definitive agreem

      9/20/24 10:33:00 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm Reports Second Quarter 2024 Financial Results

      EXETER, N.H., Aug. 12, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), today announced second quarter 2024 financial results and related highlights. Second Quarter 2024 Financial Results and Related Highlights Net revenue for the second quarter of 2024 was $16.9 million, an increase of 5.3% as compared to the second quarter of 2023Disposables revenue increased by 13.9% as compared to the second quarter of 2023U.S. disposables revenue increased by 25.9% as compared to the second quarter of 2023Gross margin in the second quarter of 2024 was 49.

      8/12/24 5:15:00 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private

      EXETER, N.H., June 17, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has signed a definitive merger agreement with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund.  Concurrently with the entry into the definitive merger agreement, our existing lender, investment affiliates managed by SLR Capital Partners ("SLR") have agreed to convert approximately $81.0 million of term debt into preferred equity of the newly-formed entity, and Perceptive will invest $50.0 million of new preferred equity capital into the b

      6/17/24 6:55:00 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Perimeter Medical Imaging AI Strengthens Leadership Team with Appointment of Experienced MedTech Executive, Adam Hodges, as Vice President, Sales and Marketing

      TORONTO and DALLAS, Sept. 8, 2023 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – today announced the appointment of experienced medtech sales executive, Adam Hodges, as its Vice President, Sales and Marketing, effective immediately. Adrian Mendes, Perimeter's Chief Executive Officer stated, "I am excited to welcome Adam to the Perimeter team as our senior leader responsible for the strategy and execution of our sales-related goals. Adam's extensive medtech b

      9/8/23 8:30:00 AM ET
      $IART
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

      SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

      12/7/22 4:05:00 PM ET
      $EAR
      $ITGR
      $VAPO
      Medical Specialities
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments

    $VAPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Vapotherm Inc.

      SC 13D/A - VAPOTHERM INC (0001253176) (Subject)

      9/24/24 7:04:57 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Vapotherm Inc.

      SC 13D/A - VAPOTHERM INC (0001253176) (Subject)

      9/20/24 10:32:59 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Vapotherm Inc.

      SC 13G - VAPOTHERM INC (0001253176) (Subject)

      7/18/24 7:24:17 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Financials

    Live finance-specific insights

    See more
    • Vapotherm To Report Second Quarter 2023 Financial Results

      Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors

      7/25/23 4:30:00 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm Reports First Quarter 2023 Financial Results

      Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced first quarter 2023 financial results. First Quarter 2023 Summary and Highlights Total revenue for the first quarter of 2023 was $17.7 million Capital revenue increased by 28% as compared to the fourth quarter of 2022 due to strong HVT 2.0 sales Disposables revenue decreased by 12% as compared to the fourth quarter of 2022 due to the timing of the US flu season Gross margin in the first quarter of 2023 was 35.0% Gross margin increased by 750 basis points over the fourth quarter of 2022 due to initial benefits from the transition of operations to Mexico For the first quarter of 2023, GAAP oper

      5/3/23 4:10:00 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm To Report First Quarter 2023 Financial Results

      Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the first quarter of 2023 after the close of trading on Wednesday, May 3, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.v

      4/27/23 4:30:00 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vapotherm downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Vapotherm from Buy to Hold and set a new price target of $5.00 from $12.00 previously

      5/6/22 7:28:09 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Vapotherm from Overweight to Underweight and set a new price target of $8.00 from $23.00 previously

      4/7/22 7:25:32 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Piper Sandler reiterated coverage on Vapotherm with a new price target

      Piper Sandler reiterated coverage of Vapotherm with a rating of Overweight and set a new price target of $36.00 from $39.00 previously

      2/25/21 7:36:13 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Vapotherm Inc.

      15-12G - VAPOTHERM INC (0001253176) (Filer)

      9/25/24 11:32:00 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Vapotherm Inc.

      EFFECT - VAPOTHERM INC (0001253176) (Filer)

      9/25/24 12:15:03 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Vapotherm Inc.

      EFFECT - VAPOTHERM INC (0001253176) (Filer)

      9/25/24 12:15:04 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care